Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5584 | Indoximod (NLG-8189) |
| Indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50 = 7 μM); disrupts tryptophan catabolism. Enhances the antitumor and antiviral immunoresponses of CD8+ T-cells in vitro. Reduces tumor volume in mice with xenografts overexpressing IDO. | |
| BCC5589 | PF-06447475 |
| Potent LRRK2 inhibitor (IC50 = 3 nM). Attenuates α-synuclein-induced dopaminergic neurodegeneration and neuroinflammation in G2019S-LRRK2 expressing rats. Also neuroprotective in wild type rats. Brain penetrant. | |
| BCC5600 | EC 144 |
| High affinity, potent and selective Hsp90 inhibitor (Ki = 0.2 nM and IC50 = 1.1 nM). Exhibits selectivity for Hsp90 over Grp94 and TRAP1 (Ki values are 61 and 255 nM respectively) and has no effect (IC50 >10 μM) against a panel of 285 kinases. Degrades Her-2 in MCF-7 breast cancer cells (EC50 = 14 nM). Blocks tumor growth and induces partial tumor regression in an N87 gastric tumor mouse model. Also inhibits LPS-induced TNFα release in an LPS shock mouse model and suppresses disease development in a rat model of collagen-induced arthritis. Exhibits <20-fold efficacy over BIIB 021 in mice. Orally available and brain penetrant. | |
| BCC5601 | CCG 203971 |
| Antifibrotic agent; inhibits fibrosis by targeting the MRTF/SRF gene transcription pathway. Selectively inhibits proliferation of SSc-derived dermal fibroblasts but not that of normal fibroblasts. Inhibits expression of CTGF, α-SMA, and COL1A2 in SSc fibroblasts as well as in LPA and in TGFβ-stimulated fibroblasts. Prevents bleomycin-induced skin thickening and collagen deposition in vivo. Also suppresses PC-3 cell migration in scratch wound assays (IC50 = 4.2 μM). | |
| BCC5602 | IWP 4 |
| Potent inhibitor of Wnt/β-catenin signaling (IC50 = 25 nM). Has minimal effect on Notch and Hedgehog signaling pathways. Induces differentiation of cardiomyocytes from human ESCs and iPSCs. | |
| BCC5608 | TC-E 5002 |
| Selective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). Inhibits growth of HeLa and KYSE-150 cancer cells in vitro. | |
| BCC5613 | SCH 51344 |
| Potent MTH1 inhibitor (Kd = 49 nM). Inhibits Ras-induced malignant transformation and increases α-actin promoter-driven CAT activity in Ras-transformed cells. Has no effect on Ras-induced ERK and JNK activation. Inhibits Ras-induced membrane ruffling in REF-52 fibroblasts and blocks anchorage-independent growth of Ras-transformed tumor cell lines. Also induces DNA damage in SW480 colon cancer cells. | |
| BCC5615 | SB 706504 |
| p38 MAPK inhibitor. Inhibits LPS-induced transcription of a range of chemokines and cytokines in chronic obstructive pulmonary disease (COPD) monocyte derived macrophages (MDMs). Also inhibits LPS-induced protein expression of IL-6, IL-10, TNFα and γ-inducible protein 10 in COPD MDMs. Effects on suppression of LPS-induced gene and protein expression are enhanced in combination with dexamethasone. | |
